Program

Sunday, December 2

Welcoming Remarks and Keynote Talks

7:00 p.m.-9:00 p.m.

T cells vs. tumor cells: Arming/deploying T cells for a successful battle
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

The molecular basis of tumor immunogenicity
Robert D. Schreiber, Washington University, St. Louis, MO

Opening Reception

9:00 p.m.-10:30 p.m.

Monday, December 3
Basic Insights Into Immune Mechanisms Promoting Cancer Development and Progression

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Inflammation and Cancer Initiation

Session Chairperson: Drew M. Pardoll, Johns Hopkins University, Baltimore, MD
8:00 a.m.-10:00 a.m.

Spontaneous and therapy-induced T cell responses to cancer
Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Berlin, Germany

T cell subsets in the tumor microenvironment
Weiping Zou, University of Michigan, Ann Arbor, MI

Dominant signaling pathways in the immune microenvironment of cancer
Drew M. Pardoll

Oncogenic driver mutations shape the nature of immune responses in tumors *
Vladislava Juric, University of California, San Francisco, CA

Vaccination against microsatellite-unstable colorectal cancer with frameshift peptide antigens *
Matthias Kloor, University Hospital Heidelberg, Heidelberg, Germany

Break

10:00 a.m.-10:30 a.m.

Poster Viewing

10:00 a.m.-7:30 p.m.

Session 2: The Tumor Microenvironment: Recent Advances

Session Chairperson: Lisa M. Coussens, Oregon Health and Science University, Portland, OR
10:30 a.m.-12:30 p.m.

Inflammation and cancer: Reprogramming the immune microenvironment as an anti-cancer therapeutic strategy
Lisa M. Coussens

Immune escape mechanisms in lymphoid malignancies
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

Regulation of myeloid-derived suppressor cells in tumor microenvironment
Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center, Tampa, FL

Myofibroblasts activated upon tissue injury and hypoxia promote development of castration-resistant prostate cancer *
Massimo Ammirante, University of California San Diego, La Jolla, CA

Restoring T cell immunosurveillance in pancreatic carcinoma using CD40 agonists *
Gregory L. Beatty, University of Pennsylvania, Philadelphia, PA

Lunch on Own/Free Time

12:30 p.m.-2:30 p.m.

Session 3: The Tumor Microenvironment: Translational Updates

Session Chairperson: Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA
2:30 p.m.-4:30 p.m.

The interplay of inflammation and cancer
Glenn Dranoff

Cancer inflammation in pancreatic carcinoma
Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

Tipping the balance from a procarcinogenic to anticancer response in pancreatic cancer
Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Aptamer-targeted delivery of Smad3 or RNF111 siRNAs renders CD8+ T cells resistant to TGFβ inhibition and potentiates vaccine-induced antitumor immunity *
Randall Brenneman, Miller School of Medicine, University of Miami, Miami, FL

Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development *
Bridget Keenan, Johns Hopkins School of Medicine, Baltimore, MD

Poster Session A/Reception

4:30 p.m.-7:00 p.m.

Dinner on Own/Evening Off

7:00 p.m.-

Tuesday, December 4
Engineering Enhanced Immune Responses to Cancer

Continental Breakfast

7:00 a.m.-8:00 a.m.

Poster Viewing

7:00 a.m.-5:30 p.m.

Session 4: Checkpoint Pathways Regulating Immune Responses to Cancer

Session Chairperson: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Immune checkpoint blockade in cancer therapy: New insights and opportunities
James P. Allison

Antibody blockade of multiple negative T cell regulators contribute to anti-tumor responses
Alan J. Korman, Bristol-Myers Squibb, Redwood City, CA

Translation of an OX40 agonist: Putting a foot on an immunologic gas pedal
Andrew D. Weinberg, Earle A. Chiles Institute, Portland, OR

Identification of novel immune check points and their implementation as mAb targets for cancer immunotherapy *
Ofer Levy, Compugen, Ltd., Tel Aviv, Israel

Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer *
Christian Klein, Roche Glycart AG, Schlieren, Switzerland

Break

10:00 a.m.-10:30 a.m.

Session 5: Advances in the Development of Combinatorial Immune-Based Therapies that Target Checkpoint Pathways

Session Chairperson: Padmanee Sharma, University of Texas MD Anderson Cancer Center, Houston, TX
10:30 a.m.-12:30 p.m.

Phase I trial of targeted therapy with PSA-TRICOM Vaccine (V) and Ipilimumab (ipi) in patients (Pts) with metastatic castration-resistant prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, MD

Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4
Padmanee Sharma

Role of PD-1 and LAG-3 in cancer immunotherapy
Charles G. Drake, Johns Hopkins University, Baltimore, MD

Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer *
Kevin C. Soares, Johns Hopkins Medical School, Baltimore, MD

Genetic analysis and therapeutic targeting of IDO pathways in cancer *
George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA

Poster Session B / Lunch

12:30 p.m.-3:00 p.m.

Session 6: Innovations in Adoptive T Cell Therapy

Session Chairperson: Carl H. June, University of Pennsylvania, Philadelphia, PA
3:00 p.m.-5:20 p.m.

Engineered T-cell therapies for cancer
Carl H. June

Preclinical models to study tumor-infiltrating chimeric antigen receptor-expressing lymphocyte hypofunction in adoptive T cell therapy (ACT)*
Edmund Moon, University of Pennsylvania, Philadelphia, PA

Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors*
Liang-Chuan S. Wang, University of Pennsylvania, Philadelphia, PA

Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants
Paul Nghiem, University of Washington, Seattle, WA

T-cell adoptive therapy for cancer: Translating the science
James C. Yang, National Cancer Institute, Bethesda, MD

Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4*
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA

Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy*
Thomas M. Schmitt, Fred Hutchinson Cancer Research Center, Seattle, WA

Dinner on Own / Evening Off

5:20 p.m.-

Wednesday, December 5
Immunotherapeutics: Focus on Human Studies

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 7: T Cell Precursors, Memory Subsets, and Control of Adoptive Therapy

Session Chairperson: Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, WA
8:00 a.m.-10:00 a.m.

Chimeric antigen receptor design and T cell subsets in adoptive therapy
Stanley Riddell

Sugar high: Glycolytic flux wrecks stem cell-like T cells
Nicholas P. Restifo, Center for Cancer Research, National Institutes of Health, Bethesda, MD

Using viruses to enhance T cell therapy for cancer
Cliona M. Rooney, Baylor College of Medicine, Houston, TX

Advanced T cell engineering for cancer immunotherapy
Michael Jensen, Seattle Children's Hospital, Seattle, WA

Break

10:00 a.m.-10:30 a.m.

Session 8: From Regulatory Pathways to Multimodality Immunotherapy Approaches: A Translational Paradigm

Session Chairperson: Ronald Levy, Stanford University, Stanford, CA
10:30 a.m.-12:30 p.m.

Cervical tissue T cells in HPV disease
Cornelia L. Trimble, Johns Hopkins University, Baltimore, MD

Endothelial regulation of T cell trafficking in tumors
George Coukos, University of Pennsylvania, Philadelphia, PA

Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain
Ronald Levy

Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer *
Lana E. Kandalaft, University of Pennsylvania, Philadelphia, PA

Genetically engineered T cells redirected against cancer associated fibroblasts to potentiate immunotherapeutic effects *
Sunitha Kakarla, Baylor College of Medicine, Houston, TX

Closing Remarks and Departure

12:30 p.m.-12:45 p.m.